Wolfgang Glaesner - Concepedia

Author

Wolfgang Glaesner

Eli Lilly (United States)

Also Known As

Glaesner W, W. Glaesner, Wolfgang Glaesner

Publications

531

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)

About

Wolfgang Glaesner is an author at Eli Lilly (United States) specializing in medicine, immunology, and autoimmunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	148
2	Engineering	1	1	18
3	Natural Sciences	1	1	116
4	Allergy	1	1	14
5	Biochemistry	1	1	116

Wolfgang Glaesner

Publications

528

Citations

H-Index

Page 1

	Year	Citations
Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein Wolfgang Glaesner, Andrew Vick, Rohn Millican, Diabetes/Metabolism Research and Reviews	2010	290
Glycosylation of Erythropoietin Affects Receptor Binding Kinetics: Role of Electrostatic Interactions Ryan J. Darling, Uma Kuchibhotla, Wolfgang Glaesner, Biochemistry GlycobiologyChemical BiologyElectrostatic InteractionsNacl ConcentrationBioanalysis	2002	116
An anti-ANGPTL3/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif Deepa Balasubramaniam, Oliver C. Schroeder, Anna M. Russell, Journal of Lipid Research	2022	46
Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide Zvonko Miličević, Greg Anglin, Kristine D. Harper, Diabetes Obesity and Metabolism	2016	27
A New Approach to Drug Therapy: Fc-Fusion Technology V. Pechtner, Karanikas CA, Garcia Perez LE, Primary Health Care Open Access EngineeringImmunologyImmune RegulationFc-fusion ProteinsPharmacotherapy	2017	18
A Model of Controlled Acute Hyperglycemia in Rats: Effects of Insulin and Glucagon-Like Peptide-1 Analog J. K. Saha, Jinqi Xia, Steven K. Engle, Journal of Pharmacology and Experimental Therapeutics	2006	17
Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care? Lotus Mallbris, Julian Davies, Andrew L. Glasebrook, PubMed ImmunologyBiological TherapyDermatologyImmunotherapyClinical Trials	2016	14

Page 1